Skip to content

    Recently Viewed

      Listening...

      Home / Media Center / Press releases /
      Global Health Equity

      Global Health Equity

      Johnson & Johnson Expands Commitment to Advance Health Equity in the United States

      Johnson & Johnson supports more than 100 community-led organizations in marginalized communities to provide resources and tools to advance accessible, quality health care in the U.S.

      Janssen Announces Promising Antiviral Activity Against Dengue in a Phase 2a Human Challenge Model

      The antiviral JNJ-1802 induced prophylactic antiviral activity against dengue in a human challenge model Dengue infects millions of people annually and could impact many more as climate change fuels outbreaks The antiviral, previously found to be safe and well-tolerated, is now in a community-based field study to establish efficacy in a real-world setting

      Johnson & Johnson Confirms Intent Not to Enforce Patents for SIRTURO® (bedaquiline) for the Treatment of Multidrug-Resistant Tuberculosis in 134 Low- and Middle-Income Countries

      Company continues to be focused on addressing perceived barriers to access and refocusing global efforts on the most-pressing barrier to access: underdiagnosis of the disease. Decision builds on a decade of Company investments in collaborative efforts to help countries sustainably scale up access and bring people living with multidrug-resistant tuberculosis (MDR-TB) into treatment.

      Janssen Announces Novel Dengue Antiviral Demonstrates Efficacy in Pre-Clinical Data Published in Nature

      The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans Findings support further clinical development for prevention and treatment of dengue, which impacts millions of people today and is poised to threaten many more due to climate change Research builds on Johnson & Johnson’s enduring commitment to beat neglected tropical diseases, including dengue

      Johnson & Johnson Launches Next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town, Focused on Antimicrobial Resistance (AMR)

      The new Center is focused on outpacing the rising threat of antimicrobial resistance (AMR) and builds on Johnson & Johnson’s longstanding commitment to tackle this challenge The Satellite Center in Cape Town is the second site to open in Johnson & Johnson’s network of research collaborations aimed at addressing the world’s most pressing health challenges The collaboration between Johnson & Johnson and H3D will help to further expand and strengthen Africa’s scientific capacity as a global hub for discovery research
      You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.